Literature DB >> 16980941

Unfavorable pathological characteristics in familial colorectal cancer with low-level microsatellite instability.

Carolien M Kets1, Nicoline Hoogerbrugge, Danielle Bodmer, Riki Willems, Han G Brunner, Joannes H J M van Krieken, Marjolijn J L Ligtenberg.   

Abstract

A high degree of microsatellite instability (MSI) in colorectal cancer (CRC) is a hallmark of hereditary non-polyposis colorectal cancer (HNPCC), caused by germline defects in the mismatch repair (MMR) genes. A low degree of instability (less than 30% of the microsatellites) is seen in a subset of tumors. To clarify the significance of this low degree of MSI phenotype, we studied the differences between patients with colorectal tumors with high-level, low-level and no MSI. Colorectal tumors with no (n = 68) and low-level (n = 18) MSI of patients clinically suspected of HNPCC were compared to colorectal tumors with high-level MSI (n = 12) of patients that carry a pathogenic germline mutation in a MMR gene. Compared to tumors with no MSI, tumors with low-level MSI were classified more frequently as stage T3 or T4 (100% vs 68% respectively), and showed less immune response (P = 0.02). No significant differences in familial CRC risk were found by comparing pedigrees of these two groups of tumors. Compared to the group of tumors with high-level MSI, the group of tumors with low-level MSI had a less suspicious family history, a higher percentage of lymph node metastasis (56 vs 17%), and less immune response. Thus, with respect to genetic risks, familial CRC can be divided into two groups: Tumors with high-level MSI and tumors with low-level or no MSI. However, tumors with low-level MSI show unfavorable pathological characteristics compared to tumors with no and tumors with high-level MSI. These differences suggest a distinct underlying biology of CRC with low-level MSI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980941     DOI: 10.1038/modpathol.3800701

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Dan Jiang; Chang Shu; Weihan Zhang; Linyong Sun; Mengni Zhang; Yanjun He; Gemma Owen; Wanjun Jin; Du He; Xiangbing Deng; Xiaoyu Liu
Journal:  Virchows Arch       Date:  2020-06-25       Impact factor: 4.064

Review 2.  Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Authors:  Kristen M Drescher; Poonam Sharma; Henry T Lynch
Journal:  Clin Dev Immunol       Date:  2010-06-10

3.  Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer.

Authors:  Astrid C Haugen; Ajay Goel; Kanae Yamada; Giancarlo Marra; Thuy-Phuong Nguyen; Takeshi Nagasaka; Shinsaku Kanazawa; Junichi Koike; Yoshinori Kikuchi; Xiaoling Zhong; Michitsune Arita; Kazutoshi Shibuya; Mitsuo Oshimura; Hiromichi Hemmi; C Richard Boland; Minoru Koi
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

4.  The association of tumor microsatellite instability phenotype with family history of colorectal cancer.

Authors:  Bharati Bapat; Noralane M Lindor; John Baron; Kim Siegmund; Lin Li; Yingye Zheng; Robert Haile; Steve Gallinger; Jeremy R Jass; Joanne P Young; Michelle Cotterchio; Mark Jenkins; John Grove; Graham Casey; Stephen N Thibodeau; D Timothy Bishop; John L Hopper; Dennis Ahnen; Polly A Newcomb; Loic Le Marchand; John D Potter; Daniela Seminara
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-03       Impact factor: 4.254

5.  Low-Level Microsatellite Instability as a Potential Prognostic Factor in Sporadic Colorectal Cancer.

Authors:  Soo Young Lee; Duck-Woo Kim; Hye Seung Lee; Myong Hoon Ihn; Heung-Kwon Oh; Byung Soh Min; Woo Ram Kim; Jung Wook Huh; Jung-A Yun; Kang Young Lee; Nam Kyu Kim; Woo Yong Lee; Hee Cheol Kim; Sung-Bum Kang
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.